SeaStar Medical Holding (ICU)
NASDAQ:ICU
Want to see ICU full AI Analyst Report?
ICU Stock Chart & Stats
$2.30
-$0.08(-3.90%)
At close: 4:00 PM EST
$2.30
-$0.08(-3.90%)
Day’s Range― - ―
52-Week Range$2.07 - $13.10
Previous CloseN/A
Volume52.61K
Average Volume (3M)3.06M
Market Cap
$15.83M
Enterprise Value$1.63M
Total Cash (Recent Filing)$9.35M
Total Debt (Recent Filing)$331.00K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 18, 2026EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.10
Shares Outstanding3,997,002
10 Day Avg. Volume1,756,841
30 Day Avg. Volume3,057,972
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.78
Price to Sales (P/S)40.32
P/FCF Ratio-3.66
Enterprise Value/Market Cap0.10
Enterprise Value/Revenue1.13
Enterprise Value/Gross Profit1.22
Enterprise Value/Ebitda-0.14
Forecast
1Y Price Target
$8.00Price Target Upside247.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$1.87M
Bulls Say, Bears Say
Bulls Say
Clinical Trial And Regulatory ProgressOngoing progress in the NEUTRALIZE-AKI clinical trial, having passed midpoint enrollment, along with preparation of regulatory submission components not contingent on trial outcomes could shorten the path to FDA review if clinical results are favorable.
Commercial ExpansionExpansion of the customer base at children's hospitals and a pipeline of several dozen additional hospitals supports broader pediatric adoption and improving device utilization.
EarningsAnalyst highlights that the company reported quarterly results that exceeded expectations on revenue, gross margin, and GAAP loss per share, indicating improving financial performance.
Bears Say
Financing RiskCurrent cash levels and ongoing cash burn imply the company will need to raise additional capital, creating financing risk for continued operations and development plans.
Share Dilution And Valuation PressureExpected share dilution from a capital raise is pressuring stock valuation and prompted the analyst to lower the price target.
SeaStar Medical Holding News
ICU FAQ
What was SeaStar Medical Holding’s price range in the past 12 months?
SeaStar Medical Holding lowest stock price was $2.07 and its highest was $13.10 in the past 12 months.
What is SeaStar Medical Holding’s market cap?
SeaStar Medical Holding’s market cap is $15.83M.
When is SeaStar Medical Holding’s upcoming earnings report date?
SeaStar Medical Holding’s upcoming earnings report date is Aug 18, 2026 which is in 86 days.
How were SeaStar Medical Holding’s earnings last quarter?
SeaStar Medical Holding released its earnings results on May 13, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.825 by -$0.075.
Is SeaStar Medical Holding overvalued?
According to Wall Street analysts SeaStar Medical Holding’s price is currently Undervalued.
Does SeaStar Medical Holding pay dividends?
SeaStar Medical Holding does not currently pay dividends.
What is SeaStar Medical Holding’s EPS estimate?
SeaStar Medical Holding’s EPS estimate is -0.97.
How many shares outstanding does SeaStar Medical Holding have?
SeaStar Medical Holding has 3,997,002 shares outstanding.
What happened to SeaStar Medical Holding’s price movement after its last earnings report?
SeaStar Medical Holding reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.825. Following the earnings report the stock price went down -8.696%.
Which hedge fund is a major shareholder of SeaStar Medical Holding?
Currently, no hedge funds are holding shares in ICU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SeaStar Medical Holding
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
ICU Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear commercial and clinical momentum: notable YoY revenue growth (+69%), seven new hospital customers in Q1, completion of the SAVE Registry enrollment (50 patients), substantial trial progress (198/339 enrolled, ~58%) and a stronger cash position (+~79% YoY). Management emphasized high gross margins (>90%), disciplined operating spend and active FDA engagement on potential accelerated pathways. Offsetting this progress are the small absolute revenue base ($495k Q1), continued quarterly net losses (~$3.5M), dependence on ultra-rare pediatric case flow for adoption, ongoing enrollment and regulatory risks, and notable share dilution. Overall, the call presents meaningful early-stage commercial validation and clinical progress but also highlights typical execution and regulatory risks for a clinical-stage medical device company.View all ICU earnings summariesICU Stock 12 Month Forecast
Average Price Target
$8.00
▲(247.83% Upside)
Technical Analysis
Ownership Overview
2.96% Insiders
0.72% Mutual Funds
<0.01% Other Institutional Investors
95.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---